Personalis Announces Pricing of Public Offering of Common Stock
12 8월 2020 - 3:20PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for population sequencing and cancer, today announced the pricing
of its previously announced underwritten public offering of
6,578,947 shares of its common stock at a price to the public of
$19.00 per share. Gross proceeds to Personalis from the offering
are expected to be $125 million, before deducting underwriting
discounts and commissions and estimated offering expenses.
In addition, the underwriters have been granted a 30-day option
to purchase up to an additional 986,842 shares of common stock from
a selling stockholder on the same terms and conditions. Personalis
will not receive any proceeds from any sale of shares by the
selling stockholder.
BofA Securities, Citigroup and Cowen are acting as joint
book-running managers. BTIG, Needham & Company and Oppenheimer
& Co. are acting as co-managers.
A shelf registration statement relating to the shares being sold
in this offering was filed with the U.S. Securities and Exchange
Commission on July 2, 2020, and was declared effective on July 10,
2020. A preliminary prospectus supplement and accompanying
prospectus relating to the offering was filed with the SEC and are
available for free on the SEC’s website located at
http://www.sec.gov. When available, electronic copies of the final
prospectus supplement and accompanying prospectus relating to the
offering may be obtained from BofA Securities, Inc., Attention:
Prospectus Department, NC1‐004‐03‐43, 200 North College Street, 3rd
floor, Charlotte, NC 28255‐0001, or by emailing
dg.prospectus_requests@baml.com; Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at 1-800-831-9146; or Cowen and Company,
LLC, c/o Broadridge Financial Solutions, Attention: Prospectus
Department, 1155 Long Island Avenue, Edgewood, New York 11717,
telephone: 631‐274‐2806.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Personalis, Inc.
Personalis, Inc. is a growing population sequencing and cancer
genomics company, with a continuing focus on scale, efficiency and
quality. In oncology, Personalis is transforming the development of
next-generation therapies by providing more comprehensive molecular
data about each patient’s cancer and immune response. The company’s
ImmunoID NeXT Platform® is designed to
adapt to the complex and evolving understanding of cancer,
providing its biopharmaceutical customers with information on all
of the approximately 20,000 human genes, together with the immune
system, from a single tissue sample. The Personalis® Clinical
Laboratory is GxP aligned as well as CLIA’88-certified and
CAP-accredited.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements relating to Personalis’ expectations regarding
the underwritten public offering. These statements are subject to
significant risks and uncertainties and actual results could differ
materially from those projected. Personalis cautions investors not
to place undue reliance on the forward-looking statements contained
in this release. These risks and uncertainties include, without
limitation, the fact that completion of the underwritten public
offering is subject to the satisfaction of customary closing
conditions. Risks and uncertainties relating to Personalis and its
business can be found in the “Risk Factors” section of Personalis’
Form 10-Q for the quarter ended June 30, 2020, filed with the SEC
on August 6, 2020, in the preliminary prospectus supplement related
to the public offering filed with the SEC on August 11, 2020, and
in the final prospectus supplement related to the public offering
to be filed with the SEC on or about August 12, 2020. Personalis
undertakes no duty or obligation to update any forward-looking
statements contained in this release as a result of new
information, future events or changes in Personalis’ expectations,
except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200811005896/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024